The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted there. Nearly 10,000 people attended the 41st Congress of the European Committee for Treatment and Research in Multiple…
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs of active inflammation in the brain, a group with limited treatment options. That’s according to new data…
Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with Gilenya (fingolimod), now the only MS therapy approved for pediatric patients in the U.S. That’s according to…
Frexalimab, a therapy Sanofi is developing for multiple sclerosis (MS) patients, led to sustained reductions in disease activity in people with relapsing forms of MS over more than two years of treatment, while continuing to show a favorable safety profile. That’s according to new data from an…
Consuming large amounts of ultra-processed foods (UPF) — products high in additives, artificial ingredients, and extensive processing — is associated with increased disease activity in people with clinically isolated syndrome (CIS), which is the first presentation of multiple sclerosis (MS), a study has found. The analysis used a…
Increasing blood vitamin D levels with high-dose supplementation can significantly reduce the risk of new disease activity in people with clinically isolated syndrome (CIS), or those who experienced a first episode of symptoms suggestive of multiple sclerosis (MS). That’s according to new data from the D-Lay-MS…
People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical decline is evident, a study found. While measures of processing speed, verbal memory, and visual memory worsened after about 2.7 years, significant changes in walking function and dexterity were only…
The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world’s largest congress dedicated to multiple sclerosis (MS) research and care, kicks off today in Barcelona. About 9,000 scientists, clinicians, industry leaders, and patient advocates from more than 100 countries are expected…
Children and adolescents who go on to develop multiple sclerosis (MS) begin visiting the emergency department more often than their peers as early as a dozen years before their first MS symptoms appear, a new study from Canada suggests. In fact, over an 18-year period, children later diagnosed…
TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi (ublituximab-xiiy) that can be injected at home. This change could offer greater convenience and flexibility for people with relapsing forms of multiple sclerosis (MS). The new formulation is given…
Health Canada is warning that glatiramer acetate products, used in the country to treat relapsing-remitting multiple sclerosis (MS), may cause a severe allergic reaction called anaphylaxis, which can be life-threatening. The warning follows 11 reported cases of anaphylactic reactions linked to Copaxone — the original brand name of glatiramer…
The United Arab Emirates became the first country to approve tolebrutinib, clearing it to treat adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). Sanofi’s oral BTK inhibitor is also the first approved therapy that directly addresses the chronic inflammation that contributes to disability progression independent of relapses. “The…
A generic version of Ampyra (dalfampridine), used to improve walking in adults with multiple sclerosis (MS), is now available in the U.S. at a price its developer said is almost $1,000 a month lower than average. Civicascript will charge pharmacies $16 for each 60-tablet bottle, and recommends…
Having better physical performance is associated with higher cognitive function in people with multiple sclerosis (MS), particularly among those with more disability, a study finds. Disability levels, in turn, correlate negatively with cognition and physical performance, with patients with moderate disability having worse scores on assessments than those with…
Switching between CD20-targeting antibodies Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) doesn’t affect either’s effectiveness at lowering disease activity and slowing disability progression in people with multiple sclerosis (MS), a real-world study in Germany shows. Researchers did see a link between switching and a faster, continuous decrease of immunoglobulin…
Three self-reported prevalent symptoms among people with multiple sclerosis (MS) – fatigue, mobility issues, and cognitive impairment – are generally not associated with lower engagement in healthy lifestyle factors, a study in Australia shows. However, in the long term, mobility difficulties may significantly reduce adherence to physical activity, a…
A research project to explore the genetic connection between the Epstein-Barr virus (EBV) and the risk of developing multiple sclerosis (MS) has been awarded a $24,400 incubator grant by the nonprofit MS Australia. Titled “A novel use of human genetics to recruit participants for MS research,” the…
Autologous hematopoietic stem cell transplant (aHSCT) could slow disease progression in people with relapsing-remitting multiple sclerosis (RRMS), according to a study tracking MS patients in Sweden. The procedure was associated with sustained reductions in biomarkers linked to progressive MS. The results also showed that a significant portion of patients…
About 62% of multiple sclerosis (MS) patients use disease-modifying therapies (DMTs) before and during pregnancy, and the medications don’t appear to harm their health or their babies’ health, recently reported data from an international registry show. Most pregnancies resulted in live, full-term births, and these births generally occurred…
A person’s total number of visits to multiple sclerosis (MS) clinics is not associated with a lower risk of death, suggesting that merely increasing the number of clinical follow-up visits is not enough to improve survival, a new study in Denmark found. Instead, factors such as being female, having…
Blood levels of a protein called GFAP, which reflects the activation and damage to support cells in the brain and spinal cord, may help predict disease severity and the response to treatment with relapsing forms of multiple sclerosis (MS), according to a new analysis of clinical trial data. “This…
Mitochondrial abnormalities, or problems in the powerhouses of cells, seem to be a main contributor to the death of important nerve cells in the cerebellum — a brain region involved in motor control — in people with multiple sclerosis (MS), a new study suggests. Researchers found that inflammation and…
A multicenter Phase 2a clinical trial testing foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has begun dosing patients at Weill Cornell Medicine Multiple Sclerosis Center in New York. The Phase 2a study (NCT06292923) is assessing the safety and efficacy of Tiziana Life Sciences‘ therapy,…
Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical stimulation to improve walking in people with multiple sclerosis (MS). The policy covers PoNS at an out-of-network negotiated price of $18,350, making Aetna, one of the largest private health…
Four Canadian nurses are among the 11 recipients of this year’s International Nightingale Awards, which support innovative projects aimed at improving care for people with multiple sclerosis (MS). Presented annually by the International Organization of Multiple Sclerosis Nurses (IOMSN), the awards are open to MS nurses living…
Ocrevus (ocrelizumab) appears to be safe and effective for children and adolescents with multiple sclerosis (MS), according to real-world data from Kuwait. After about 15 months of treatment, more than 90% of patients with pediatric-onset MS (POMS) remained free of relapses, and most also showed no new…
Wandercraft has launched Walk in New York, a new rehabilitation center that offers access to its advanced mobility devices for people with severe walking impairments, including those with multiple sclerosis (MS). The center provides sessions with neurological rehabilitation therapists and walking sessions with its robotic exoskeleton,…
The Multiple Sclerosis Association of America (MSAA) will host its 11th annual Improving Lives Benefit on May 14 to bring together members of the multiple sclerosis (MS) community, celebrate achievements, and raise support for the organization’s free programs and services. The fundraising event will take place at…
While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis (SPMS) in the Netherlands, it did not significantly change their risk of developing cardiovascular disease, a small study showed. Individual cardiovascular risk factors and 10-year risk estimation tools showed no significant changes…
Intimacy and sexuality among people with multiple sclerosis (MS) will be the focus of this year’s Holistic Health and Wellness Forum for MS, presented by Yoga Moves MS — a U.S. program aiming to improve quality of life for those with neuromuscular conditions — on May 21 in Michigan…
Get regular updates to your inbox.
